P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
Niels W.C.J. van de Donk(Oncode Institute), María‐Victoria Mateos(Hospital Clínico San Carlos), Alfred L. Garfall(University of Pennsylvania), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Laura Rosiñol Dachs(Hospital Clínic de Barcelona), Lotfi Benboubker, Alfredo Perales‐Puchalt(The Wistar Institute), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Caroline Hodin(Janssen (Belgium)), Katarina Uttervall(Karolinska University Hospital), Kaz Groen(Amsterdam University Medical Centers), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes)
Cited by 5
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k